• 5 min read
• Published on 7 November 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
Every so often, a politician's handshake does more for a market than a decade of research and development. To me, the recent deal struck by the Trump administration to get weight-loss drugs covered by Medicare looks exactly like one of those moments. It’s a classic policy catalyst, the kind of government intervention that doesn't just nudge a market, it shoves it into a whole new league. Suddenly, a treatment that was the preserve of the wealthy and well-insured is on the cusp of becoming accessible to millions of older Americans. And where government money flows, investor opportunity often follows.
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
Let’s be clear about what’s happened here. The drugs themselves, these GLP-1 agonists from the likes of Eli Lilly and Novo Nordisk, are nothing short of remarkable. They work. For many people, they work astonishingly well, achieving results that years of miserable dieting and gym-going could never touch. The problem has always been the price tag. It’s one thing to have a miracle cure, it’s quite another to afford it.
By bringing these treatments under the Medicare umbrella for the first time, the game has fundamentally changed. This isn't just about a discount. It’s about unlocking a vast, previously untapped patient population. Think of it as a dam bursting. The demand was always there, held back by a wall of cost. Now, that wall has a whopping great hole in it, and a flood of new patients is about to pour through. For the big pharmaceutical players, this is obviously terrific news.
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
Of course, piling into the two giants, Eli Lilly and Novo Nordisk, is the obvious trade. It’s probably not a bad one, either. But I think the more interesting story lies in the ripples this wave will create across the entire healthcare pond. When a market expands this quickly, it creates opportunities for the smaller, more nimble fish swimming in the giants' wake. The whole situation creates a fascinating set of Obesity Drug Stocks: Medicare Coverage Trade-offs for investors to consider.
The most compelling area, to my mind, is the race to create an oral alternative. Let’s be honest, most people would rather pop a pill than give themselves a weekly injection. It’s just human nature. The company that cracks the code for a safe, effective, and convenient oral GLP-1 drug could be sitting on a goldmine. Firms like Structure Therapeutics are working on this very problem, and whilst it’s a high-risk game, the potential rewards are enormous.
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
The opportunity doesn’t stop with the drugmakers, either. A successful weight-loss journey isn't just about the medicine. It’s about managing a person's overall health. This means a greater need for companies like DexCom, which makes continuous glucose monitors. As more people manage their metabolic health with these new drugs, the demand for sophisticated monitoring tools is likely to rise in tandem.
Then you have the companies tackling related conditions. Obesity is often linked to other nasty ailments, like the liver disease MASH. As doctors get a handle on their patients' weight, they will turn their attention to fixing the associated damage. This could create a significant tailwind for specialised firms like Madrigal Pharmaceuticals. It’s the classic "picks and shovels" play in a gold rush. You don't have to find the gold yourself, you can make a tidy profit selling the tools to the prospectors.
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
View the full Basket:Obesity Drug Stocks: Medicare Coverage Trade-offs
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article